tiprankstipranks
Sona Nanotech Welcomes New CMO, Advances Patent Filing
Company Announcements

Sona Nanotech Welcomes New CMO, Advances Patent Filing

Sona Nanotech Inc (TSE:SONA) has released an update.

Don't Miss Our Christmas Offers:

Sona Nanotech Inc. has announced the appointment of Dr. Carman Giacomantonio as Chief Medical Officer, bringing his expertise in cancer immunotherapy to lead the company’s Targeted Hyperthermia Therapy clinical trials. Additionally, Sona has filed a U.S. provisional patent for a gold nanorod conjugation technique aimed at targeted drug delivery, with plans to expand it to international patents. Dr. Giacomantonio has been granted 750,000 stock options as part of the company’s incentive plan, enhancing his involvement in their innovative medical technologies.

For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech Reports Promising Cancer Therapy Results
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech Advances Cancer Therapy Research
TipRanks Canadian Auto-Generated NewsdeskSona Nanotech Secures Patent and Strengthens Leadership
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App